Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma

Seagen has long held on to Adcetris as one of its top-selling and expanded products, and the latest data for the drug, used in combination with other therapies, show that the Washington state-based biotech is looking to continue that strategy.